IPA
Income statement / Annual
Last year (2024), ImmunoPrecise Antibodies Ltd.'s total revenue was $24.52 M,
an increase of 18.65% from the previous year.
In 2024, ImmunoPrecise Antibodies Ltd.'s net income was -$27.18 M.
See ImmunoPrecise Antibodies Ltd.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
Period Ended |
04/30/2024 |
04/30/2023 |
04/30/2022 |
04/30/2021 |
04/30/2020 |
04/30/2019 |
04/30/2018 |
04/30/2017 |
04/30/2016 |
12/31/2014 |
Operating Revenue |
$24.52 M |
$20.67 M |
$19.36 M |
$17.91 M |
$14.06 M |
$10.93 M |
$5.44 M |
$2.63 M |
$1.90 M |
$1.76 M |
Cost of Revenue |
$12.47 M
|
$9.10 M
|
$8.38 M
|
$6.37 M
|
$6.02 M
|
$5.63 M
|
$2.99 M
|
$1.21 M
|
$298,319.00
|
$265,333.00
|
Gross Profit |
$12.05 M
|
$11.56 M
|
$10.98 M
|
$11.54 M
|
$8.03 M
|
$5.29 M
|
$2.45 M
|
$1.42 M
|
$1.60 M
|
$1.50 M
|
Gross Profit Ratio |
0.49
|
0.56
|
0.57
|
0.64
|
0.57
|
0.48
|
0.45
|
0.54
|
0.84
|
0.85
|
Research and Development Expenses |
$4.04 M
|
$12.28 M
|
$6.69 M
|
$1.97 M
|
$446,280.00
|
$485,845.00
|
$509,248.00
|
$660,408.00
|
$302,769.00
|
$621,639.00
|
General & Administrative Expenses |
$15.59 M
|
$19.81 M
|
$16.97 M
|
$12.65 M
|
$7.95 M
|
$7.65 M
|
$6.31 M
|
$6.70 M
|
$997,291.00
|
$64,835.00
|
Selling & Marketing Expenses |
$3.54 M
|
$3.61 M
|
$740,000.00
|
$691,000.00
|
$377,728.00
|
$819,250.00
|
$134,680.00
|
$119,192.00
|
$20,830.00
|
$6,693.00
|
Selling, General & Administrative Expenses |
$19.14 M
|
$23.42 M
|
$17.71 M
|
$13.34 M
|
$8.33 M
|
$8.47 M
|
$6.45 M
|
$6.82 M
|
$1.02 M
|
$64,835.00
|
Other Expenses |
-$11.13 M
|
$0.00
|
$2.75 M
|
$132,000.00
|
$2.65 M
|
$1.91 M
|
$256,519.00
|
$376,776.00
|
$340,317.00
|
$1,040.00
|
Operating Expenses |
$12.05 M
|
$39.78 M
|
$27.15 M
|
$15.71 M
|
$12.08 M
|
$11.52 M
|
$7.21 M
|
$7.84 M
|
$1.66 M
|
$65,875.00
|
Cost And Expenses |
$24.52 M
|
$48.88 M
|
$35.53 M
|
$22.09 M
|
$18.10 M
|
$17.15 M
|
$10.20 M
|
$7.84 M
|
$1.66 M
|
$65,875.00
|
Interest Income |
$23,000.00
|
$270,000.00
|
$279,000.00
|
$282,000.00
|
$272,006.00
|
$30,085.00
|
$73,004.00
|
$0.00
|
$9,308.00
|
$0.00
|
Interest Expense |
$19,000.00
|
$30,000.00
|
$419,000.00
|
$863,000.00
|
$1.44 M
|
$1.32 M
|
$50,591.00
|
$16,216.00
|
$9,308.00
|
$338.00
|
Depreciation & Amortization |
$5.74 M
|
$6.69 M
|
$3.77 M
|
$3.71 M
|
$3.41 M
|
$2.26 M
|
$458,079.00
|
$50,609.00
|
$41,881.00
|
$1,040.00
|
EBITDA |
-$22.95 M |
-$21.04 M |
-$11.99 M |
-$1.42 M |
-$449,000.00 |
-$4.03 M |
-$4.32 M |
-$5.40 M |
$293,835.00 |
$368,573.00 |
EBITDA Ratio |
-0.94
|
-1.03
|
-0.63
|
-0.01
|
-0.03
|
-0.36
|
-0.82
|
-1.96
|
0.15
|
-0.04
|
Operating Income Ratio |
-0.56
|
-1.26
|
-0.81
|
-0.37
|
-0.29
|
-0.57
|
-0.91
|
-0.53
|
0.13
|
-0.02
|
Total Other Income/Expenses Net |
-$14.94 M
|
-$2.14 M
|
-$67,000.00
|
-$2.08 M
|
-$1.47 M
|
-$1.09 M
|
-$517,849.00
|
-$4.08 M
|
$221,182.00
|
-$25,100.00
|
Income Before Tax |
-$28.70 M
|
-$27.75 M
|
-$15.85 M
|
-$6.00 M
|
-$5.29 M
|
-$7.61 M
|
-$5.06 M
|
-$5.47 M
|
$242,646.00
|
-$62,313.00
|
Income Before Tax Ratio |
-1.17
|
-1.34
|
-0.82
|
-0.33
|
-0.38
|
-0.7
|
-0.93
|
-2.08
|
0.13
|
-0.04
|
Income Tax Expense |
-$1.53 M
|
-$1.19 M
|
$861,000.00
|
$1.35 M
|
-$345,728.00
|
$4,788.00
|
$109,715.00
|
-$82,378.00
|
$91,611.00
|
$338.00
|
Net Income |
-$27.18 M
|
-$26.56 M
|
-$16.71 M
|
-$7.34 M
|
-$4.95 M
|
-$7.62 M
|
-$5.17 M
|
-$5.38 M
|
$151,035.00
|
-$62,313.00
|
Net Income Ratio |
-1.11
|
-1.29
|
-0.86
|
-0.41
|
-0.35
|
-0.7
|
-0.95
|
-2.05
|
0.08
|
-0.04
|
EPS |
-1.06 |
-1.07 |
-0.85 |
-0.45 |
-0.36 |
-0.61 |
-0.57 |
-1.36 |
0.1 |
-0.11 |
EPS Diluted |
-1.06 |
-1.07 |
-0.85 |
-0.45 |
-0.36 |
-0.61 |
-0.57 |
-1.36 |
0.1 |
-0.11 |
Weighted Average Shares Out |
$25.64 M
|
$24.90 M
|
$19.69 M
|
$16.47 M
|
$13.63 M
|
$12.54 M
|
$9.11 M
|
$3.96 M
|
$1.92 M
|
$550,129.00
|
Weighted Average Shares Out Diluted |
$25.64 M
|
$24.90 M
|
$19.69 M
|
$16.47 M
|
$13.63 M
|
$12.54 M
|
$9.11 M
|
$3.96 M
|
$1.92 M
|
$550,129.00
|
Link |
|
|
|
|
|
|
|
|
|
|